Vienna, Austria
November 12 - November 13, 2010
During this meeting there was official live Twitter streaming. The Twitter stream has been captured and you can follow this link to login and download a transcript of the Twitter stream
Aim of the conference
The treatment of multiple sclerosis is entering in a new era with the introduction of drugs that are characterized by novel mechanism of action, routes of administration, dosages and markers of efficacy and safety. These new compounds will not replace the ones already available, but will be combined with them in complex therapeutic protocols that will offer innovative options for treatment personalization, according to patient’s and disease’s characteristics, and will be aimed to reach ambitious goals such as 'freedom from disease activity'. The aims of this Conference were to provide a comprehensive overview of the scientific background of these drugs and give an opportunity to discuss how the daily practice will be adjusted to optimize patients’ management.
Learning objectives
Upon completion of this activity, participants will be:
- Updated on pharmacological targets of drugs that will be introduced in the treatment of multiple sclerosis
- Informed about the available evidence concerning efficacy and safety of these new drugs
- Updated on the implementation of these new therapeutic options in daily practice
- Knowledgeable about ‘freedom from disease activity’ as a therapeutic goal in multiple sclerosis
Target audience
This program is appropriate for clinicians and scientists involved in multiple sclerosis management.
Serono Symposia International Foundation (www.seronosymposia.org) will submit this program “Multiple Sclerosis: Future Treatments and New Goals” (Vienna, Austria - November 12-13, 2010) for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME).
